Hepatocellular carcinoma (HCC) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-HEMOCHROMATOSIS-HCC-PREVENTION-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-HCC`
Sources	`SRC-AASLD-HCC-2023` `SRC-NCCN-BCELL-2025` `SRC-NCCN-HCC-2025`

Notes

STUB — v0.3 chronic-condition prevention pilot (hemochromatosis / HCC). Two-Co-Lead signoff queued. Phlebotomy + AASLD surveillance is one of the highest-evidence chronic-condition prevention combinations across the v0.3 pilot set.

Used By

Indication

IND-HEMOCHROMATOSIS-HCC-PREVENTION-OBSERVATION - IND-HEMOCHROMATOSIS-HCC-PREVENTION-OBSERVATION

Red flag

RF-HEMOCHROMATOSIS-HCC-PREVENTION - Hereditary hemochromatosis (HFE-related; C282Y homozygous genotype primarily, compound C2...